

Accepted Manuscript

mGlu₄ allosteric modulation for treating Parkinson's disease

Delphine Charvin

PII: S0028-3908(18)30138-2

DOI: [10.1016/j.neuropharm.2018.03.027](https://doi.org/10.1016/j.neuropharm.2018.03.027)

Reference: NP 7130

To appear in: *Neuropharmacology*


Received Date: 19 January 2018

Revised Date: 20 March 2018

Accepted Date: 21 March 2018

Please cite this article as: Charvin, D., mGlu₄ allosteric modulation for treating Parkinson's disease, *Neuropharmacology* (2018), doi: 10.1016/j.neuropharm.2018.03.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



mGlu₄ allosteric modulation for treating Parkinson's Disease

Delphine Charvin

Prexton Therapeutics, 14 chemin des Aulx, Plan-les-Ouates, 1228, Switzerland

Delphine.Charvin@prextontherapeutics.com

Abstract:

2017 is the 200th anniversary of the first published description of Parkinson's disease (PD). Fifty years ago, the clinical benefit of levodopa was first documented, representing the most important advance in the treatment of PD so far. Among the novel targets identified in the last decade, positive allosteric modulators (PAM) of mGlu₄ receptors show great promise, with the potential to change the paradigm of the PD treatment approach. mGlu₄ PAMs have shown consistent efficacy in various preclinical models of PD, and entered clinical trials for the first time in 2017. This review synthesizes the rationale for mGlu₄ PAM development for PD and progress to date, reporting the key achievements from preclinical studies to the first-in-class compound assessment in man.

Keywords: Parkinson's disease; dyskinesia; glutamate; dopamine; mGlu₄

Abbreviations: **6-OHDA:** 6-hydroxydopamine; **ADX88178:** 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine; **AIM:** abnormal involuntary movements; **CODA-RET:** complemented donor acceptor resonance energy transfer; **D1:** dopamine receptor type 1; **D2:** dopamine receptor type 2; **GABA:** gamma-aminobutyric acid; **GPe/i:**

Download English Version:

<https://daneshyari.com/en/article/8516622>

Download Persian Version:

<https://daneshyari.com/article/8516622>

[Daneshyari.com](https://daneshyari.com)